VCM
NBIX icon

Voleon Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Voleon Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Buy
7,638
+1,137
+17% +$151K 0.02% 438
2025
Q4 		$922K Sell
6,501
-11,791
-64% -$1.71M 0.02% 456
2025
Q3 		$2.57M Buy
+18,292
New +$2.48M 0.06% 286

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voleon Capital Management's NBIX Position: Q1 2026 in Review

Voleon Capital Management increased its Neurocrine Biosciences (NBIX) stake by 17% in Q1 2026, buying an estimated $151K and bringing the position to 7,638 shares worth $1.01M. The position accounts for 0.02% of the portfolio, ranked #438.

Voleon Capital Management first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.57M in Q3 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Voleon Capital Management held 7,638 shares of Neurocrine Biosciences worth $1.01M as of Q1 2026.
  • Voleon Capital Management bought 1,137 Neurocrine Biosciences shares in Q1 2026, an estimated $151K.
  • Neurocrine Biosciences made up 0.02% of Voleon Capital Management's portfolio in Q1 2026, its #438 holding.
  • Voleon Capital Management first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Voleon Capital Management's Neurocrine Biosciences position peaked at $2.57M in Q3 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.